PharmaGap fka GAP

[Tackler]

How can this keep going up?

51.4% of the company is controlled by the chairman Roderick M. Bryden.

Following conversion of all outstanding debentures held by Stormont (but excluding debentures held by arm's-length parties), including accrued interest to April 4, 2008, and exercise of all attached warrants, Stormont would hold 40,379,085 of 63,823,843 common shares outstanding, representing a 63.27-per-cent interest (51.4 per cent on a fully diluted basis). Stormont is controlled by Roderick M. Bryden, chairman of PharmaGap.

Everything is in the money now so completely and fully diluted: 40,379,085/.514 = 78,558,531 shares